Patents by Inventor Asna Masood

Asna Masood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF
    Publication number: 20170058031
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Inventors: David John King, Alison WITTE, Heidi N. LEBLANC, Richard THEOLIS, Asna MASOOD, Mark YAMANAKA, Kyra D. ZENS, Sarah R. REED, Tim SPROUL, Chetana RAO-NAIK, David Passmore, Dawn M. TANAMACHI, Kristopher TOY
  • Human antibodies that bind CD22 and uses thereof
    Patent number: 9499632
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: November 22, 2016
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF
    Publication number: 20130230530
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: February 20, 2013
    Publication date: September 5, 2013
    Applicant: Medarex, Inc.
    Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Human antibodies that bind CD22 and uses thereof
    Patent number: 8481683
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 9, 2013
    Assignee: Medarex, Inc.
    Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • GPCR crystalization method using an antibody
    Publication number: 20110166330
    Abstract: An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex.
    Type: Application
    Filed: February 2, 2011
    Publication date: July 7, 2011
    Inventors: Brian Kobilka, Daniel Rohrer, Peter Brams, Asna Masood
  • Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3)
    Patent number: 7947807
    Abstract: An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: May 24, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Brian Kobilka, Dan Rohrer, Peter Brams, Asna Masood
  • Human Antibodies That Bind Cd22 And Uses Thereof
    Publication number: 20100143368
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Application
    Filed: November 30, 2007
    Publication date: June 10, 2010
    Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Emory, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore
  • GPCR crystalization method using an antibody
    Publication number: 20090148510
    Abstract: An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex.
    Type: Application
    Filed: September 19, 2008
    Publication date: June 11, 2009
    Inventors: Brian Kobilka, Daniel K. Rohrer, Peter Brahms, Asna Masood